News

Relmada Therapeutics Welcomes Urologic Expert to Advisory Team

Relmada Therapeutics Welcomes Urologic Expert to Advisory Team

Relmada Therapeutics Welcomes Max Kates to Clinical Advisory Board

Renowned for his expertise in bladder cancer, Dr. Max Kates has joined the Clinical Advisory Board at Relmada Therapeutics, Inc. This appointment is a strategic move aimed at bolstering the development of NDV-01, a potential treatment for non-muscle invasive bladder cancer (NMIBC).

Expertise in Bladder Cancer Research

Dr. Kates, an Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, is a prominent figure in the urologic oncology field. His leadership as chair of the groundbreaking Phase 3 BRIDGE trial positions him as a key asset for Relmada’s upcoming clinical initiatives, particularly the NDV-01 Phase 3 program set to begin in the near future.

Commitment to Advancing Cancer Treatments

Relmada Therapeutics has expressed enthusiasm about Dr. Kates' contributions during the Phase 3 trials. His insight into the practical challenges of high-volume urologic oncology will help shape the program, enhancing its relevance and effectiveness. Chief Medical Officer Dr. Raj Pruthi stated, "Max’s substantial experience will enrich our understanding of the complexities of bladder cancer treatment and improve the design of our clinical strategies."

Initial Data and Future Potential

Dr. Kates shared that his leadership in the BRIDGE study has deepened his appreciation for innovative treatment options such as NDV-01. The promising early safety and efficacy data for NDV-01 showcased at a recent urology conference highlight its potential to change the landscape of NMIBC treatment. His commitment to advancing this program underscores a shared goal among clinical experts and researchers to provide effective treatment solutions for bladder cancer patients.

NDV-01: A Revolutionary Approach

NDV-01 represents a new frontier in bladder cancer therapy. This sustained-release formulation of gemcitabine and docetaxel is designed for easy in-office administration, enhancing drug retention while minimizing systemic exposure. The convenience and efficacy of NDV-01 present a compelling option for both patients and healthcare providers in managing NMIBC.

Understanding Non-Muscle Invasive Bladder Cancer

NMIBC accounts for a significant majority of bladder cancer cases, making the development of effective treatments like NDV-01 crucial. With high recurrence rates and limited conventional options available, the impact of NDV-01 could be considerable. This therapy's innovative approach seeks to serve not only as a first-line treatment but also as a valuable solution for patients who are not responding well to existing therapies.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is at the forefront of clinical-stage biotechnology, focusing on novel therapies for challenging oncology and central nervous system conditions. The company's unwavering commitment to addressing unmet medical needs drives their efforts in developing transformative treatments, including NDV-01 and their other candidate, sepranolone, currently progressing through clinical trials.

Frequently Asked Questions

What role does Max Kates play at Relmada Therapeutics?

Max Kates has been appointed to the Clinical Advisory Board to guide the development of NDV-01 for bladder cancer treatment.

What is NDV-01?

NDV-01 is a sustained-release formulation intended for the treatment of non-muscle invasive bladder cancer, integrating gemcitabine and docetaxel for effective results.

When is the NDV-01 Phase 3 program expected to begin?

The Phase 3 program for NDV-01 is expected to start in the first half of 2026.

Why is bladder cancer treatment important?

Bladder cancer is prevalent and often recurs, impacting many patients. Effective treatments like NDV-01 can significantly improve patient outcomes.

How does Relmada Therapeutics contribute to cancer treatment innovation?

Relmada focuses on developing novel therapies that address significant unmet needs in cancer treatment, aiming for groundbreaking solutions like NDV-01.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 141

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 15

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 80

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 107

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 93

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 61

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 135

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading

Top 5 Most Recently Viewed Articles

Blue Moon Metals Secures C$60 Million for Strategic Growth

Updated Category News Views 164

Blue Moon Metals Announces Major Financing Initiative Blue Moon Metals Inc. (TSXV: MOON; OTCQX: BMOOF), based in Toronto, is embarking on an exciting new phase as the company has entered a letter agreement with key financial partners. These partners include Scotiabank and Canaccord Genuity Corp., who are playing a pivotal role as joint bookrunners in this financial...

Continue Reading
Theravance Biopharma Engages Investors at Upcoming Conference

Updated Category News Views 330

Theravance Biopharma's Upcoming Investor Conference Participation Theravance Biopharma, Inc. (NASDAQ: TBPH) is eager to actively engage with the investment community during a significant event. The company is set to take part in a Fireside Chat at an upcoming health conference, where it will discuss its ongoing projects and recent advancements in its pipeline. This event...

Continue Reading
Bright Green Partners with Benuvia for Raw Material Supply

Updated Category News Views 238

Bright Green Partners with Benuvia Operations Bright Green Corporation (Nasdaq: BGXX) has announced an important partnership through a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leading name in pharmaceutical cannabinoids. This collaboration highlights Bright Green's dedication and capability to...

Continue Reading
EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Osisko Development Unveils Comprehensive Insights on Cariboo Gold

Updated Category News Views 258

Osisko Development Releases Technical Report for Cariboo Gold Project Osisko Development Corp. has taken a significant step in its journey to develop the Cariboo Gold Project by filing a comprehensive technical report. This report, prepared in line with the National Instrument 43-101 guidelines, highlights the feasibility study results for this promising site. The Cariboo...

Continue Reading